FDA Corrects Email Address in Drug Pilot Program Notice
Published Date: 7/6/2026
Notice
Summary
The FDA fixed a small but important mistake in their June 24, 2026 notice about a new pilot program to speed up drug testing while keeping people safe. This correction updates the contact email so anyone interested can send their thoughts and questions to the right place. If you're involved in drug development or clinical trials, this means you can now easily join the conversation without delay.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-13591 — Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy or keep big chunks of banks or bank companies, and the Federal Reserve is checking their plans to make sure everything’s fair and safe. If you want to share your thoughts, you’ve got until July 21, 2026, to speak up. This process helps keep banks strong and protects your money!
Next: 2026-13593 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is checking in on some paperwork rules to make sure they’re useful and not too tricky, especially for small businesses. They want your thoughts on how to make these forms easier and better, with a deadline to share ideas by September 4, 2026. This review affects about 200 businesses and nonprofits, each spending around 2 hours on these forms.